Document is current
Any future updates will be listed below
-
Authors
Bergamaschi, Cristina https://orcid.org/0000-0003-1030-2662
Pandit, Hrishikesh https://orcid.org/0000-0003-0994-6778
Nagy, Bethany A https://orcid.org/0000-0001-7454-9344
Stellas, Dimitris https://orcid.org/0000-0002-7787-3921
Jensen, Shawn M https://orcid.org/0000-0002-4843-5930
Bear, Jenifer https://orcid.org/0000-0001-5065-6081
Cam, Maggie
Valentin, Antonio
Fox, Bernard A https://orcid.org/0000-0002-4452-5947
Felber, Barbara K https://orcid.org/0000-0001-8925-8128
Pavlakis, George N https://orcid.org/0000-0002-4027-4036
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02452268 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
https://doi.org/10.1136/jitc-2021-003388
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
https://doi.org/10.1136/jitc-2023-007725
Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10
https://doi.org/10.1136/jitc-2020-000599
-
Funding
Funding for this research was provided by:
Novartis (CRADA #02199)
- License Information
